Immunization Technologies: Time to Consider New Preventative Solutions for Respiratory Syncytial Virus Infections
- Catherine Weil-Olivier; David Salisbury; José Navarro-Alonso; Chryssoula Tzialla; Yan Zhang; Susanna Esposito
Access Resources
About
This article commentary discusses new ways to prevent respiratory syncytial virus (RSV) infections in infants. It highlights the use of long-acting monoclonal antibodies, like nirsevimab, which offer protection during an infant's first RSV season. These antibodies work like vaccines but are considered passive immunization. It emphasizes the need for updated regulations to include these new methods in national immunization programs and ensure broad access for all infants. It also mentions ongoing research and potential future strategies, such as maternal vaccines, to further protect against RSV infections in young children.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.